Cao et al. reported on the use of CD7 autologous CAR-T cells in a young female with R/R AML with a complex karyotype, TP53 deletion, FLT3-ITD mutation and SKAP2–RUNX 1 fusion gene: CD7 CAR-T cells were administered after lymphodepletion with decitabine, fludarabine and cyclophosphamide; 17 days after CAR-T cells infusion, the patient achieved morphologic leukemia-free state (MLFS). This evidence concerns the gene CD7 and leukemia.